Jupiter Life Line Hospitals Limited
₹256.30-₹4.40 (-1.7%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹8,877 Cr
- P/E
- 46.3x
- EV / EBITDA
- 34.5x
- Revenue
- ₹1,060 Cr
- Net margin
- 16.6%
- ROCE
- 18.2%
Price chart
Technical chartScreen technicals →-83.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +1.1%
- 3M
- -22.9%
- 6M
- -79.1%
- 1Y
- -83.9%
- 5Y
- -75.9%
52-week range
Day change -₹4.40 (-1.7%) from ₹261 to ₹256 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in JLHL, bought on each weekday since 2023.
AI Summary
Indian StockStrengths1
- Strong 5-year net profit CAGR of 38.3%
Concerns0
Rule-based from financial data. Not advice.
About the company
Jupiter Life Line Hospitals Limited, a multi-specialty hospital, provides health care services under the Jupiter brand in India.
Read moreShow less
Jupiter Life Line Hospitals Limited, a multi-specialty hospital, provides health care services under the Jupiter brand in India. The company offers treatments in the areas of bariatric surgery, breast care center, cardiac surgery, cardiology, chest medicine, dental care, dermatology, endocrinology and diabetes, ENT, gastroenterology, general surgery and minimal access surgery, hematology and BMT, HPB and surgical gastroenterology, infectious diseases, internal medicine, interventional radiology, mental health, nephrology, neurology, neurosurgery, nutrition and dietetics, Obs and gynecology, oncology, ophthalmology, organ transplant, orthopedics, pediatrics, pain clinic, plastic and cosmetic surgery, rehabilitation, rheumatology, robotic knee replacement, robotic surgery, TAVI/TAVR, and urology. It also operates hotel under the Fortune Park Lake City Hotel name in Thane. The company was incorporated in 2002 and is based in Mumbai, India.
- Sector
- Healthcare
- Shares outstanding
- 6.6 Cr shares
- ISIN
- INE682M01012
- BSE code
- 543980
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹8,877 Cr
- P/E
- 46.3x
- P/B
- 5.9x
- EV / EBITDA
- 34.5x
- EV / Sales
- 9.5x
- P/S
- 9.7x
- Earnings yield
- 2.2%
- 52-week high
- ₹1,596.40
- 52-week low
- ₹238.85
Profitability
- Operating margin
- 24.8%
- Net margin
- 16.6%
- EBITDA margin
- 27.7%
- ROE
- 12.2%
- ROCE
- 18.2%
- ROA
- 11.2%
- Dividend payout
- 4.0%
- Tax rate
- 25.0%
- Other income, % of PBT
- 12.7%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,060 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 15.8%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 14.6%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹253 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 17.7%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 21.7%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 38.3%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹110 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -40.2%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹348 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 53.8%
Solvency and efficiency
- Current ratio
- 7.15
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- Interest coverage
- 11.95
- Financial leverage
- 1.09
- CFO / Net profit
- 0.72
- Cash / Market cap
- 8.0%
- Cash per share
- ₹108.53
- Asset turnover
- 0.67
- Fixed asset turnover
- 1.92
- Capital intensity
- 0.52
- Debtor days
- 18 days
- Inventory turnover
- 9.36
- Cash conversion cycle
- -59 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹17 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹791 Cr |
| Sales | Operating profit | ₹269 Cr |
| Operating profit | Interest | ₹9 Cr |
| Operating profit | Depreciation | ₹42 Cr |
| Operating profit | Profit before tax | ₹218 Cr |
| Other income | Profit before tax | ₹28 Cr |
| Profit before tax | Tax and other | ₹61 Cr |
| Profit before tax | Net profit | ₹185 Cr |
Revenue and net profit
Revenue grew 15.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹461 Cr | ₹17 Cr |
| FY2022 | ₹657 Cr | ₹85 Cr |
| FY2023 | ₹787 Cr | ₹107 Cr |
| FY2024 | ₹915 Cr | ₹152 Cr |
| FY2025 | ₹1,060 Cr | ₹185 Cr |
Cash flows
FY2025: ₹220 Cr from operations, ₹47.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹113 Cr | ₹35 Cr |
| FY2022 | ₹142 Cr | ₹74 Cr |
| FY2023 | ₹184 Cr | ₹54 Cr |
| FY2024 | ₹110 Cr | -₹128 Cr |
| FY2025 | ₹220 Cr | ₹47 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,060 Cr+15.8%1Y
- Net profit
- ₹185 Cr+21.7%1Y
- Cash from operations
- ₹220 Cr
- Free cash flow
- ₹47 Cr
- Revenue CAGR, 5Y
- 14.6%
- EBITDA CAGR, 5Y
- 24.4%
- Net profit CAGR, 5Y
- 38.3%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,060 Cr | ₹269 Cr | — | ₹185 Cr | ₹220 Cr | ₹47 Cr | 13.0% | +15.8% | +21.7% |
Monthly returns
Month-by-month returns of JLHL across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹1,710 Cr |
| Equity capital | ₹66 Cr |
| Reserves | ₹1,357 Cr |
| Borrowings | ₹142 Cr |
| Other liabilities | ₹145 Cr |
| Assets | ₹1,710 Cr |
| Fixed assets | ₹713 Cr |
| Capital work in progress | ₹163 Cr |
| Investments | ₹208 Cr |
| Other assets | ₹626 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
JLHL trades at 46.3x earnings against a peer median of 52.6x (a 12% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Jupiter Life Line Hospitals LimitedJLHLthis companyP/E ↓ discount | ₹8,877 Cr | 46.3x | 5.9x | 12.2% | 34.5x |
| HealthCare Global Enterprises LimitedHCG | ₹9,408 Cr | 513.0x | 8.0x | 2.8% | 49.9x |
| Sanofi India LtdSANOFI | ₹9,387 Cr | 25.4x | 12.0x | — | — |
| Jeena Sikho Lifecare LimitedJSLL | ₹8,968 Cr | 58.2x | 25.2x | 35.9% | 90.3x |
| PROCTER & GAMBLE HEALTH LIMITEDPGHL | ₹8,946 Cr | 29.2x | 14.4x | — | — |
| Corona Remedies LimitedCORONA | ₹8,749 Cr | 55.1x | — | 18.8% | 55.0x |
| Blue Jet Healthcare LimitedBLUEJET | ₹8,659 Cr | 24.6x | 6.9x | 19.4% | 34.4x |
| STRIDES PHARMA SCIENCE LIMITEDSTAR | ₹8,552 Cr | 112.0x | 2.7x | 1.3% | 35.5x |
| Sequent Scientific LimitedVIYASH | ₹8,288 Cr | 531.0x | 4.1x | 0.1% | 633.5x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
JLHL since 1 January, against earlier years.
Historical volatility
JLHL's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 15.0% |
| FY2022 | 24.0% |
| FY2023 | 26.0% |
| FY2024 | 25.0% |
| FY2025 | 25.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,060 Cr |
| Costs | |
| Interest | ₹9 Cr |
| Expenses | ₹791 Cr |
| Operating profitOperating Profit | ₹269 Cr |
| Other income and charges | |
| Profit before tax | ₹246 Cr |
| Tax | |
| Net profitNet Profit | ₹185 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹1,710 Cr |
| Equity capitalEquity Capital | ₹66 Cr |
| Reserves | ₹1,357 Cr |
| Borrowings | ₹142 Cr |
| Other liabilitiesOther Liabilities | ₹145 Cr |
| AssetsTotal Assets | ₹1,710 Cr |
| Fixed assetsFixed Assets | ₹713 Cr |
| Capital work in progressCWIP | ₹163 Cr |
| Investments | ₹208 Cr |
| Other assetsOther Assets | ₹626 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹220 Cr |
| Investing cash flowCash from Investing Activity | -₹173 Cr |
| Financing cash flowCash from Financing Activity | ₹302 Cr |
| Change in cashNet Cash Flow | ₹348 Cr |
Learn while you research
Academy chapters picked for Jupiter Life Line Hospitals Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 46.3, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read